The global non-invasive cancer diagnosis market is anticipated to grow at a CAGR of 7.2% during the forecast period (2021-2027). The rising prevalence of cancer cases such as breast cancer, lung cancer, blood cancer, among others, increasing awareness for the treatment of cancer, and rising FDA approvals, are driving the non-invasive cancer diagnostics market during the forecast period. For instance, according to the US Breast Cancer Statistics, around 49,290 new cases of non-invasive breast cancer are estimated to diagnose in 2021. As per the American Cancer Society, around new cases of lung cancer 235,760 (119,100 in men and 116,660 in women), and deaths of around 131,880 due to lung cancer (69,410 in men and 62,470 in women) estimated in the US in 2021.
Browse the full report description of "Global Non-Invasive Cancer Diagnosis Market Size, Share & Trends Analysis Report by Type (Blood Cancer, Solid Tumors, Breast Cancer, Lung Cancer, and Others), By Techniques (Clinical Chemistry, Immunochemistry/Immunoassay, Molecular Diagnostics, and Other Clinical Instruments), Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/non-invasive-cancer-diagnostics-market
Further, in December 2020, Hologic, Inc., a medical technology company that majorly focuses on improving women’s health, had announced that the U.S. Food and Drug Administration (FDA) approved the Genius AI Detection technology. The Genius AI Detection technology is a deep learning-based program that aids radiologists in detecting subtle possible cancers in tomosynthesis images of the breast. Besides, in May 2019, Novartis AG had announced that the US Food and Drug Administration, approved Piqray (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, advanced or metastatic breast cancer. In September 2020, the Progranulin ELISA kit from A&G Pharmaceuticals Inc. was used to examine the relationship between progranulin serum level and disease status and survival in patients with metastatic breast cancer. However, the demand for the treatment of cancers, new drugs, and FDA approvals, and the increasing prevalence of cancer patients could impede the global non-invasive cancer diagnosis market over the coming years.
Market Coverage
o By Type
o By Techniques
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Non-Invasive Cancer Diagnosis Market Report Segment
By Type
By Techniques
Global Non-Invasive Cancer Diagnosis Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/non-invasive-cancer-diagnostics-market